Hexem Bio Inc.

Hexem Bio Inc. , founded in 2024 and based in New York, specializes in innovative stem cell therapy, focusing on rejuvenating aged Hematopoietic Stem Cells to restore their functionality for enhanced health. Hexem Bio Inc. is engaged in pioneering research and development of stem cell therapies.

The company was established in New York, US. In April 2026, Hexem Bio Inc. raised USD 10. 4 million in seed funding led by Draper & Associates Inc, with participation from Seraphim Space Manager and SOSV.

The founder's individual history or previous ventures is not detailed. Hexem Bio specializes in innovative stem cell therapy, particularly focusing on rejuvenating aged Hematopoietic Stem Cells (HSCs) to restore their youthful functionality. Their core offering is the Rejuvenated Stem Cell Therapy, which aims to enhance the production of healthy blood cells, including stronger white blood cells for improved immunity, red blood cells for better organ health, and increased platelet production for faster recovery. The therapy employs the Yolk Sac Method to access the early developmental state of HSCs, validated through extensive animal studies.

Target markets include healthcare facilities and research institutions that cater to patients in need of advanced regenerative therapies, primarily in North America and parts of Europe. Hexem Bio's revenue model revolves around partnerships with healthcare providers and research institutions that implement their stem cell therapies. Transactions are structured as direct sales or partnerships, granting clients access to the Rejuvenated Stem Cell Therapy as a specialized service. The company collaborates directly with medical facilities to establish agreements that outline service delivery and pricing, which reflect the advanced nature of the therapy and tailored client solutions.

Hexem Bio Inc. is focused on expanding its product line, planning to introduce new therapies that complement their existing offerings, although specific product launch dates have not been disclosed. The company plans to utilize the April 2026 funding to further its work on stem cell rejuvenation.